Enfortumab Vedotin-Ejfv

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Advanced or Metastatic Solid Malignancies

Drug Information

Target Indication

Advanced or Metastatic Solid Malignancies

Clinical Trial

Last updated: 1/12/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

MRTX

Mirati Therapeutics, Inc.

Related Pipeline

Advanced Cancer

Carcinoma, Non-Small-Cell Lung

Metastatic Non-Squamous Non-Small Cell Lung Cancer

Clear Cell Renal Cell Carcinoma

Advanced Non-Small Cell Lung Cancer